Cargando…

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

BACKGROUND: Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT(1A)) receptors in phase III clinical development for the treatment of schizophrenia. OBJECTIVE: This study aimed to investigate the effect of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukada, Hironobu, Chen, Yu-Luan, Xiao, Guangqing, Lennek, Lisa, Milanovic, Snezana M., Worden, MaryAlice, Polhamus, Daniel G., Chiu, Yu-Yuan, Hopkins, Seth C., Galluppi, Gerald R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684410/ https://www.ncbi.nlm.nih.gov/pubmed/37882999 http://dx.doi.org/10.1007/s40262-023-01317-4

Ejemplares similares

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
por: Heffernan, Michele L. R., et al.
Publicado: (2021)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
por: Cho, Hyun-Jong, et al.
Publicado: (2015)

Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin
por: Sumsakul, Wiriyaporn, et al.
Publicado: (2016)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
por: Perini, Francesca, et al.
Publicado: (2023)

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS
por: Hopkins, Seth C., et al.
Publicado: (2022)

Cytochrome P450 in living donor liver transplantation
por: Chiu, King-Wah, et al.
Publicado: (2015)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
por: Han, Ji Min, et al.
Publicado: (2020)

Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine
por: Amponsah, Seth Kwabena, et al.
Publicado: (2020)

The Cytochrome P450 Homepage
por: Nelson, David R
Publicado: (2009)

Correlation of Cytochrome P450 Oxidoreductase Expression with the Expression of 10 Isoforms of Cytochrome P450 in Human Liver
por: Zhang, Hai-Feng, et al.
Publicado: (2016)

Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
por: Campelo, Diana, et al.
Publicado: (2018)

The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
por: Furuse, Maizumi, et al.
Publicado: (2021)

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
por: Garimella, Tushar, et al.
Publicado: (2017)

Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats
por: Li, Jiapeng, et al.
Publicado: (2016)

Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
por: Schink, Michael, et al.
Publicado: (2017)

The FMN “140s Loop” of Cytochrome P450 Reductase Controls Electron Transfer to Cytochrome P450
por: Rwere, Freeborn, et al.
Publicado: (2021)

Fungal cytochrome P450 database
por: Park, Jongsun, et al.
Publicado: (2008)

Cytochrome P450 humanised mice
por: Gonzalez, Frank J
Publicado: (2004)

Intronic polymorphisms of cytochromes P450
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2010)

The Role of Cytochromes P450 in Infection
por: Stavropoulou, Elisavet, et al.
Publicado: (2018)

Cytochromes P450, Oxygen, and Evolution
por: Lewis, David F.V., et al.
Publicado: (2001)

1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology
por: de Montellano, Paul R Ortiz
Publicado: (2018)

Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain
por: Burris-Hiday, Sarah D., et al.
Publicado: (2023)

Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response
por: Fonseca, Francina, et al.
Publicado: (2011)

Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague–dawley Rats
por: Kim, Sang-Bum, et al.
Publicado: (2015)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
por: Na, Young-Guk, et al.
Publicado: (2019)

Polymorphisms in Cytochrome P450 are associated with Extensive Efavirenz Pharmacokinetics and CNS Toxicities in an HIV Cohort in Botswana
por: Vujkovic, Marijana, et al.
Publicado: (2018)

Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients
por: Htun, Yi Yi, et al.
Publicado: (2020)

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
por: Kuvarzin, Savelii R., et al.
Publicado: (2023)

Enzyme Activity of Natural Products on Cytochrome P450
por: Zuo, Hua-Li, et al.
Publicado: (2022)

Cytochrome P450-Mediated Phytoremediation using Transgenic Plants: A Need for Engineered Cytochrome P450 Enzymes
por: Kumar, Santosh, et al.
Publicado: (2012)

Diversity and evolution of cytochrome P450 monooxygenases in Oomycetes
por: Sello, Mopeli Marshal, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ns74jul0sgifkgvuk6sjkee86d